Progesterone - TherapeuticsMD

Drug Profile

Progesterone - TherapeuticsMD

Alternative Names: TX-002HR; TX-005HR; TX-007HR; TX-12-002HR

Latest Information Update: 17 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator TherapeuticsMD
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Amenorrhoea

Most Recent Events

  • 28 Feb 2017 Suspended - Phase-I for Amenorrhoea in USA (Transdermal) (TherapeuticsMD 10-K, March 2017)
  • 28 Feb 2017 Suspended - Preclinical for Amenorrhoea in USA (Topical) (TherapeuticsMD 10-K, March 2017)
  • 01 Aug 2016 Phase-I clinical trials in Amenorrhoea in USA (Transdermal) (TherapeuticsMD pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top